Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829604 | 0.85 | HSD17B1 (0.49) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL14830198 | 0.84 | NPC1 (0.46) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL14829915 | 0.79 | MEN1 (0.47) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL14829343 | 0.78 | HPGD (0.55) | NPC1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL14830044 | 0.78 | MAPT (0.49) | MEN1KMT2AMAPTPOLBLMNA | |
| SCHEMBL14830114 | 0.77 | DOT1L (0.47) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL14829377 | 0.77 | TDP1 (0.43) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL27293915 | 0.77 | MAPT (0.56) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL14829298 | 0.77 | MEN1 (0.47) | NPC1MEN1KMT2AMAPTPOLB | |
| SCHEMBL1758782 | 0.75 | TRPA1 (0.52) | NPC1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | claimed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, RAF1 | NPC1 3037/4885MEN1 909/4885KMT2A 1685/4885 |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | NPC1 4181/4885MEN1 2225/4885KMT2A 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.